^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    KLRC2 (Killer Cell Lectin Like Receptor C2)

    i
    Other names: KLRC2, Killer Cell Lectin Like Receptor C2, NKG2C, NKG2-C Type II Integral Membrane Protein, NKG2-C, CD159c, Killer Cell Lectin-Like Receptor Subfamily C, Member 2, CD159 Antigen-Like Family Member C, Natural Killer Cell Receptor G2-C, NKG2-C-Activating NK Receptor, NK Cell Receptor C, CD159c Antigen
    Associations

    News

    Trials
    4d
    Single-Cell Sequencing Combined with RNA Sequencing Reveals the Role of Natural Killer Cells in Prognosis and Immunotherapy Response in Cervical Squamous Cell Carcinoma. (PubMed, Crit Rev Immunol)
    This study, integrating single-cell and RNA sequencing, revealed the heterogeneity of NK cells in CSCC. The risk prognostic model provided prognostic biomarkers and therapeutic targets for CSCC patients, offering a theoretical foundation for immunotherapy research.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • KLRC2 (Killer Cell Lectin Like Receptor C2) • PTGER4 (Prostaglandin E Receptor 4)
    2ms
    Single-cell transcriptomics reveals systemic immune dysregulation in non-segmental vitiligo. (PubMed, Front Immunol)
    This study provides the single-cell atlas of PBMCs in GP-NSV, uncovering profound transcriptional and compositional alterations across multiple immune cell subsets in active vitiligo. These findings offer novel insights into systemic immune dysregulation in GP-NSV and pave the way for novel targeted therapeutic strategies.
    Journal
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • EGR1 (Early Growth Response 1) • KLRC2 (Killer Cell Lectin Like Receptor C2)
    9ms
    Biological and prognostic insights into the prostaglandin D2 signaling axis in lung adenocarcinoma. (PubMed, Front Pharmacol)
    These findings were further supported by RT-qPCR and immunofluorescence data, which confirmed the downregulation of PTGDS and PTGDR in LUAD tumor tissues compared to normal tissues. Collectively, these results suggest that PGD2 and its signaling axis play a significant role in tumor-suppressive and anti-inflammatory effects in LUAD, with potential applications in prognosis management and therapy decision-making.
    Journal
    |
    CD8 (cluster of differentiation 8) • DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1) • KLRC2 (Killer Cell Lectin Like Receptor C2) • PTGDR (Prostaglandin D2 Receptor 2) • PTGDS (Prostaglandin D2 Synthase)
    11ms
    Prognostic value of natural killer T cell related genes in acute myeloid leukemia. (PubMed, Cancer Cell Int)
    This study identified key prognostic genes in AML and highlighted the critical role of NKT cells in AML pathogenesis. The study provides new insights and potential biomarkers for understanding AML biology, prognosis, and therapeutic targets.
    Journal
    |
    CD8 (cluster of differentiation 8) • IKZF3 (IKAROS Family Zinc Finger 3) • GZMB (Granzyme B) • RUNX3 (RUNX Family Transcription Factor 3) • GZMH (Granzyme H) • KLRB1 (Killer Cell Lectin Like Receptor B1) • KLRC2 (Killer Cell Lectin Like Receptor C2) • STAT4 (Signal Transducer And Activator Of Transcription 4)
    1year
    Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer. (PubMed, Breast Cancer Res)
    Our study showed that CTL and NK cell-associated gene expression and protein levels differ significantly according to TIL levels and that CTL-NK score and distribution of TILs within tumors have a prognostic value. These findings emphasize the importance of CTLs and NK cells as well as the spatial uniformity of TIL infiltration in clinical outcome of TNBC patients, providing valuable insights for refining prognostic assessments and guiding immunotherapeutic strategies.
    Journal • Tumor-infiltrating lymphocyte • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • GZMB (Granzyme B) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • KLRC2 (Killer Cell Lectin Like Receptor C2)
    over1year
    Potential molecular mechanisms of ETV6-RUNX1-positive B progenitor cell cluster in acute lymphoblastic leukemia revealed by single-cell RNA sequencing. (PubMed, PeerJ)
    HLAE-KLRC1 and TGFB1-(TGFBR1+TGFBR2). This study outlined the immune cell landscape of ETV6-RUNX1 ALL and identified chromosome 6p amplification in B progenitor cells, described the major B progenitor cell cluster driving cell cycle progression and its potential regulatory mechanisms on NK cells and T cells, providing cellular and molecular insights into ETV6-RUNX1 ALL.
    Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • HLA-E (Major Histocompatibility Complex, Class I, E) • TGFB1 (Transforming Growth Factor Beta 1) • E2F1 (E2F transcription factor 1) • KLRC1 (Killer Cell Lectin Like Receptor C1) • KLRC2 (Killer Cell Lectin Like Receptor C2) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    |
    Chr amplification(6p)
    over1year
    NKG2C/KLRC2 tumor cell expression enhances immunotherapeutic efficacy against glioblastoma. (PubMed, J Immunother Cancer)
    This study explored the role of neoplastic NKG2C/KLRC2 expression in shaping the immune profile of GBM and suggests that it is a predictive biomarker for positive responses to immune checkpoint inhibitor treatment in patients with GBM. Future studies could further validate this finding in prospective trials.
    Journal • PD(L)-1 Biomarker • IO biomarker • Tumor cell
    |
    KLRC1 (Killer Cell Lectin Like Receptor C1) • KLRC2 (Killer Cell Lectin Like Receptor C2)
    almost2years
    Integrated Analysis of Single-Cell and Bulk RNA Sequencing Data Reveals Memory-like NK Cell Subset Associated with Mycobacterium tuberculosis Latency. (PubMed, Cells)
    These data were validated by flow cytometry analysis in a small cohort of samples, showing that LTBI subjects have a significant expansion of NK cells characterized by the prevalence of memory-like CD52+ NKG2C+ NK cells. Altogether, our results provide some new information on the role of NK cells in protective immune responses to Mtb.
    Journal
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD52 (CD52 Molecule) • KLRC2 (Killer Cell Lectin Like Receptor C2)
    |
    CD52 expression
    2years
    Deciphering the immune landscape of head and neck squamous cell carcinoma: A single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapy. (PubMed, PLoS One)
    The study also found that Tregs had a dense communication network with cluster two, and that certain ligand-receptor pairs, including SPP1/CD44, HLA-E/KLRC2, HLA-E/KLRK1, ANXA1/FPR3, and CXCL9/FCGR2A, had notable changes after the therapy. These changes in gene expression and cell interactions may have implications for the role of Tregs in the TME and in response to Nivolumab therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • LAG3 (Lymphocyte Activating 3) • CD276 (CD276 Molecule) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • SPP1 (Secreted Phosphoprotein 1) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • LY9 (Lymphocyte Antigen 9) • ANXA1 (Annexin A1) • HLA-E (Major Histocompatibility Complex, Class I, E) • FCGR2A (Fc fragment of IgG receptor IIa) • FOXP3 (Forkhead Box P3) • GZMA (Granzyme A) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1) • FPR3 (Formyl Peptide Receptor 3) • KLRC2 (Killer Cell Lectin Like Receptor C2) • NKG2D (killer cell lectin like receptor K1)
    |
    PD-1 expression • LAG3 expression • CTLA4 expression
    |
    Opdivo (nivolumab)
    over2years
    A novel immune-related gene signature for predicting immunotherapy outcomes and survival in clear cell renal cell carcinoma. (PubMed, Sci Rep)
    IRGPM might be a promising biomarker of immunotherapeutic responses in patients with ccRCC. Overall, the established IRGPM was valuable for predicting survival, reflecting the immunotherapy response and immune microenvironment in patients with ccRCC.
    Journal • Gene Signature • IO biomarker
    |
    SAA1 (Serum Amyloid A1) • CSF2 (Colony stimulating factor 2) • IL4 (Interleukin 4) • KLRC2 (Killer Cell Lectin Like Receptor C2) • ANGPTL3 (Angiopoietin Like 3) • SEMA3G (Semaphorin 3G)
    over2years
    Single-Cell Transcriptomics Reveals Adaptive NK Cell and Antigen-Specific T Cell Responses Shaped by CMV Viremia Post-Hematopoietic Stem Cell Transplant (ASH 2023)
    Conclusions We delineated NK cell and antigen-specific T cell dynamics in the unique setting of allo-HSCT and CMV reactivation, highlighting the manyfold expansion of donor-derived T cell clones and the expansion and evolution in the transcriptional profile of adaptive NK cells during CMV viremia. Our study sheds light on the immunobiology of these two cell types with implications in transplant outcome and translational relevance as cancer immunotherapy.
    IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • CD14 (CD14 Molecule) • FCGR3A (Fc Fragment Of IgG Receptor IIIa) • KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3) • TRB (T Cell Receptor Beta Locus) • KLRC1 (Killer Cell Lectin Like Receptor C1) • KLRC2 (Killer Cell Lectin Like Receptor C2) • NKG2D (killer cell lectin like receptor K1)